MIAMI BEACH, Fla., Oct. 27, 2023 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report third quarter 2023 financial results before market open on Friday, November 10, 2023, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.
The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13741347 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.elitebodysculpture.com. A replay of the webcast will be available for approximately 90 days.
About AirSculpt
AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Investor Contact:
Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Stephanie Evans Greene
Chief Marketing Officer
AirSculpt Technologies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.59 |
Daily Change: | -0.09 -5.36 |
Daily Volume: | 400,970 |
Market Cap: | US$92.030M |
December 17, 2024 November 08, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load